Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer

SIMPLE SUMMARY: In breast cancer oncology, great progress has been made towards a more personalised approach. In particular, the introduction of genomic signature testing has helped physicians select the best adjuvant treatment for hormone-receptor-positive, human epidermal growth factor receptor-2–...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Flavia, Gaudio, Mariangela, Benvenuti, Chiara, De Sanctis, Rita, Santoro, Armando, Zambelli, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817989/
https://www.ncbi.nlm.nih.gov/pubmed/36612144
http://dx.doi.org/10.3390/cancers15010148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817989/
https://www.ncbi.nlm.nih.gov/pubmed/36612144
http://dx.doi.org/10.3390/cancers15010148

Ejemplares similares